Glaxosmithkline
GlaxoSmithKline plc (GSK) is a leading global healthcare company headquartered in Brentford, London. Founded in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, GSK operates in over 100 countries, with significant presence in Europe, North America, and emerging markets. The company is primarily focused on pharmaceuticals, vaccines, and consumer healthcare, aiming to improve the quality of human life by enabling people to do more, feel better, and live longer. GSK's core products include innovative medicines in areas such as respiratory, HIV, and oncology, alongside a robust vaccine portfolio that addresses infectious diseases. Notably, GSK has achieved recognition for its commitment to research and development, investing heavily in new therapies and technologies. With a strong market position, GSK continues to be a key player in the global healthcare landscape, dedicated to advancing health outcomes worldwide.
DitchCarbon Score
How does Glaxosmithkline's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Instruments industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Glaxosmithkline's score of 69 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Glaxosmithkline's reported carbon emissions
In 2023, GlaxoSmithKline (GSK) reported global carbon emissions of approximately 581,000 tonnes CO2e for Scope 1, 64,000 tonnes CO2e for Scope 2, and 8,995,000 tonnes CO2e for Scope 3. This reflects a commitment to significant reductions in greenhouse gas emissions across its operations. GSK has set ambitious targets, aiming to reduce absolute Scope 1 and 2 emissions by 80% by 2030 from a 2020 baseline, and to achieve net-zero emissions across its value chain by 2045. GSK's near-term targets include a 34% reduction in absolute Scope 1 and 2 emissions by 2025 from a 2017 base year, alongside a 16% reduction in Scope 3 emissions by 2030. The company is also committed to long-term reductions, targeting a 90% decrease in both Scope 1 and 2 emissions and Scope 3 emissions by 2045, again using 2020 as the baseline year. These initiatives align with GSK's participation in the Science Based Targets initiative (SBTi) and its commitment to the Business Ambition for 1.5°C, demonstrating a proactive approach to addressing climate change and reducing its carbon footprint in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 851,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 745,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 16,093,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Glaxosmithkline is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
